AIM ImmunoTech Participates in Virtual Investor KOL Connect Segment
AIM ImmunoTech (NYSE American: AIM) has released a Virtual Investor KOL Connect segment featuring Dr. Charles Lapp, the company's Consulting Medical Officer and founder of the Hunter-Hopkins Center.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
AIM ImmunoTech (NYSE American: AIM) has released a Virtual Investor KOL Connect segment featuring Dr. Charles Lapp, the company's Consulting Medical Officer and founder of the Hunter-Hopkins Center. The segment focuses on the results from AIM's Phase 2 study of Ampligen® for Post-COVID fatigue condition (AMP-518). Dr. Lapp, a Key Opinion Leader with over 25 years of experience treating Chronic Fatigue Syndrome and Fibromyalgia, discusses the study's findings regarding efficacy and safety.
Details
News Market Reaction – AIM
The recorded move for AIM in the trading session of this news was +0.93%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Segment featuring Dr. Charles Lapp, ME/CFS Key Opinion Leader and founder of the Hunter-Hopkins Center is now available here
OCALA, Fla., Dec. 06, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today announced the release of a Virtual Investor KOL Connect segment featuring Dr. Charles Lapp, AIM’s Consulting Medical Officer. Dr. Lapp is also the founder of the Hunter-Hopkins Center in Charlotte, N.C., and a Key Opinion Leader who has been treating Chronic Fatigue Syndrome and Fibromyalgia for over 25 years.
As part of the segment, Dr. Lapp discussed results from AIM’s Phase 2 study evaluating the efficacy and safety of Ampligen® as a potential therapeutic for people with the Post-COVID condition of fatigue (“AMP-518”; NCT05592418).
The Virtual Investor KOL Connect Segment can be accessed here.
About AIM ImmunoTech Inc.
AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company’s lead product is a first-in-class investigational drug called Ampligen® (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system.
For more information, please visit aimimmuno.com and connect with the Company on X, LinkedIn, and Facebook.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.